Dermacase

Answer to Dermacase continued from page 1095

3. Keloid

Keloids are benign hyperproliferations of dense connective tissue covered by thin epidermis. Their formation is attributed to abnormal cutaneous wound healing after injury or inflammation. They are distinct from hypertrophic scars in 2 important ways: keloids extend beyond the borders of the original wound or inflammatory process and do not regress spontaneously. They present as firm nodules that are either skin-coloured or erythematous, with telangiectases. In addition to cosmetic concerns, keloids can also be painful and pruritic. Keloids might impose psychosocial burdens on the patient and, depending on their location, might also cause functional limitations.

Keloids most commonly appear on the chest, shoulders, upper back, back of the neck, and earlobes. Keloids have also been reported in other locations, such as the genitals. Needles do not commonly cause keloids unless the injection stimulates an inflammatory reaction, as in the case of the bacille Calmette-Guérin vaccine. Keloids can develop up to 1 year after resolution of the initial injury. Although keloid recurrence is more likely in areas of higher stretch tension, such as the chest wall and the scapular and suprapectoral regions, the earlobes, an area of low tension, are a common site for keloid development. Keloids are more prevalent among people of African, Hispanic, and Asian descent, with higher incidence during pregnancy and puberty. While keloids might be slightly more common in women, this is likely attributable to the fact that women are more likely to pierce their earlobes.

The etiology of keloids is believed to involve environmental and genetic factors. Studies of families that show a propensity toward keloid formation have suggested that a degree of genetic susceptibility might exist; however, specific susceptibility genes have not yet been identified. This has raised the possibility of genetic heterogeneity, in which different genes contribute to the formation of keloids in different families. Histologically, keloids contain excess extracellular matrix, particularly glycosaminoglycans and collagen. The collagen of keloidal tissue is arranged in whorls, whereas the collagen of normal tissue is arranged in a regular pattern parallel to the epidermis. The production of excess collagen has been attributed to the fibroblasts found within keloidal tissue. Compared with the fibroblasts of normal scar tissue, these fibroblasts produce excess amounts of growth factors and have higher numbers of growth factor receptors on their surfaces, lower growth factor requirements in vitro, lower rates of apoptosis, and lower levels of apoptosis-related genes. This causes the tightly regulated process of wound healing to go awry and ultimately leads to keloid formation.

Prevention

Prevention of keloids is an important consideration. Risk factors include previous keloids, positive family history of keloids, tension at the site of trauma, and dark skin. It is recommended that patients with these risk factors avoid body-piercings and unnecessary or elective surgeries in order to reduce the likelihood of keloid formation over the scar. Postoperatively, the application of a silicone or non-silicone gel patch for 12 hours a day for at least 1 month might decrease the likelihood of keloid formation.

Treatment

While treating keloids is challenging, a number of treatment modalities have been developed. These include intralesional steroid injections (ISIs), surgical excision, cryotherapy, radiotherapy, laser treatment, silicone gel treatment, and immune-response modifiers and anti-metabolites. Combining 2 or more of these modalities is advantageous. Examples are discussed below.

Intralesional steroid injections. Intralesional steroid injections flatten, soften, and reduce the symptoms of the keloid, but rarely cause the keloid to resolve completely. Triamcinolone acetonide is a glucocorticoid that is often the agent of choice, and is injected at concentrations of 10 to 40 mg/mL based on the size of the keloid. The injections must be repeated several times, with 4- to 6-week intervals between administrations. While ISI is easy to use, well-tolerated, and effective, the side effects include telangiectases, skin atrophy, and hyperpigmentation or hypopigmentation. Cushing syndrome and anaphylaxis secondary to ISI have been reported. A local anesthetic can be employed to alleviate the injection-associated pain. Intralesional steroid injections are often used in combination with other treatments, such as surgical excision, occlusion therapy, cryotherapy, or laser therapy. The latter 2 modalities help soften the keloid to make ISI administration easier. Surgical excision is not recommended as a stand-alone therapy owing to the high associated recurrence rates.
**Cryotherapy.** Cryotherapy can be used to treat small keloids and has been shown to have a synergetic effect when used in combination with triamcinolone acetonide ISL. Multiple treatments are needed and a 15- to 30-second freeze-thaw cycle is typically employed. The associated pain can be prevented with local anesthetic. Darker-skinned individuals might experience depigmentation; in such cases cryotherapy should generally be avoided.

**Radiotherapy.** This treatment modality is especially effective when used immediately after surgical excision of the keloid. Several techniques are used, including superficial x-ray therapy, an electron beam, and low- or high-dose-rate brachytherapy. Owing to the risk of carcinogenesis, radiotherapy for keloids should be undertaken with caution in patients younger than 21 years of age.

**Laser therapy.** While earlier attempts to use lasers produced unacceptably high recurrence rates, the 585-nm pulsed-dye laser has shown more promise. In some cases, it is used to soften the keloid in preparation for ISL or, more commonly, used afterward to deal with residual erythema.

**Silicone gel dressings.** These should be applied immediately after surgical excision and worn for 12 hours a day for at least a month. The dressings occlude and hydrate the scar and appear to be somewhat beneficial in preventing keloid recurrences.

Other treatments that are still under investigation include an immune response modifier (ie, imiquimod) and 2 antimetabolites (ie, 5-fluorouracil and bleomycin). Two small studies used imiquimod after surgical excision of a keloid and reported low recurrence rates over a 24-week follow-up period. Antimetabolites are administered intralesionally and have also shown varying levels of efficacy in small trials, although they have yet to be investigated with larger randomized controlled trials.

Ms Ench is a second-year medical student at Queen’s University in Kingston, Ont. Dr Barankin is a dermatologist practicing in Toronto, Ont.

**Competing interests**

None declared

**References**